Genmab — Februar 2018

[AaBforever]

Rolig bibob...den kommer ned i 1000...i dag

[AaBforever]

Men spændende hvordan US ender ud i aften.

[JKY_VH]

luk i 1046

[Helge_LarsenPI-redaktør]

God morgen.

[Sukkeralf]

Fra SA årsregnskab

[Sukkeralf]

Tisotumab Vedotin Program Highlights

[Sukkeralf]

Planned Pivotal Trial: Seattle Genetics and Genmab plan to advance tisotumab vedotin into a pivotal phase 2 trial for recurrent or metastatic cervical cancer that relapses or progresses after standard of care treatment for cervical cancer. The single-arm trial is designed to enroll approximately 100 women and could support registration under the FDA’s accelerated approval regulations. The trial is expected to begin in the first half of 2018.

[Sukkeralf]

Expanding Clinical Development Program: Seattle Genetics and Genmab plan to initiate in 2018 a phase 2 trial of tisotumab vedotin as part of a combination regimen in women with first-line metastatic cervical cancer. In addition, a phase 2 trial is expected to begin in 2018 to evaluate tisotumab vedotin monotherapy in a range of other solid tumor types.

[Sukkeralf]

Ikke nyt men bare en bekræftigelse

[Helge_LarsenPI-redaktør]

Tak for info Sukker.

[Sukkeralf]

Udover deres BCMA ADC med GSK går de yderligere efter BCMA med denne:

[Sukkeralf]

AACR Presence: Data from multiple research and early clinical abstracts will be featured at the American Association for Cancer Research (AACR) annual meeting being held April 14-18, 2018. Included will be preclinical data on SEA-BCMA, a novel empowered antibody using Seattle Genetics’ proprietary Sugar Engineered Antibody (SEA) technology. SEA-BCMA is expected to advance into a phase 1 clinical trial for multiple myeloma during 2018.

[Sukkeralf]

SA er ude nogen tvivl det mest succesfulde ADC selskab, så godt det er her Genmabs satsede på ADC - det giver trods alt en stor tiltro

[JKY_VH]

tak Sukkeralf og god morgen

[E_L]

Fidelity still likes Genmab https://www.reuters.com/article/europe-stocks/live-markets-fidelity-sees-value-in-european-drugmakers-tech-stocks-idUSL8N1PW6GT

[bibob]

God morgen. og tak Sukkeralf og E L.

[bibob]

Håber vi kan bevare 1040 som bund. Men desværre nok ingen stigning uden nyheder. ( gode )

[StockBull]

En partneraftale er velkommen og en god 2018 guiding m.h.t Darzalex salg.

[Sukkeralf]

NBI steg pænt i går efter luk, så måske lidt håb athente fra det generelle marked

[E_L]

Seattle Genetics (SGEN) Q4 2017 Results - Earnings Call Transcript - with prominent mention and some further colour on tisotumab vedotin - https://seekingalpha.com/article/4143833-seattle-genetics-sgen-q4-2017-results-earnings-call-transcript?part=single